These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1648745)

  • 1. Modifications of social conflict-induced analgesic and activity responses in male mice receiving chronic opioid agonist and antagonist treatments.
    Teskey GC; Kavaliers M
    Pharmacol Biochem Behav; 1991 Mar; 38(3):485-93. PubMed ID: 1648745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of opiate agonists and antagonists on aggressive encounters and subsequent opioid-induced analgesia, activity and feeding responses in male mice.
    Teskey GC; Kavaliers M
    Pharmacol Biochem Behav; 1988 Sep; 31(1):43-52. PubMed ID: 3252259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex and day-night differences in opiate-induced responses of insular wild deer mice, Peromyscus maniculatus triangularis.
    Kavaliers M; Innes DG
    Pharmacol Biochem Behav; 1987 Jul; 27(3):477-82. PubMed ID: 3659070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delta but not mu-opioid receptors in the spinal cord are involved in antinociception induced by beta-endorphin given intracerebroventricularly in mice.
    Suh HH; Tseng LF
    J Pharmacol Exp Ther; 1990 Jun; 253(3):981-6. PubMed ID: 2162954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of central opiate receptor subtypes in the circulatory responses of awake rabbits to graded caval occlusions.
    Evans RG; Ludbrook J; Van Leeuwen AF
    J Physiol; 1989 Dec; 419():15-31. PubMed ID: 2559974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches to the evaluation of opioid agonists and antagonists upon the isolated, electrically stimulated mouse vas deferens preparation.
    Smith CB
    NIDA Res Monogr; 1987; 76():288-94. PubMed ID: 2830524
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic selective blockade of mu opioid receptors produces analgesia and augmentation of the effects of a kappa agonist.
    Walker MJ; Lê AD; Poulos CX; Cappell H
    Brain Res; 1991 Jan; 538(2):181-6. PubMed ID: 1849435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Action at the mu receptor is sufficient to explain the supraspinal analgesic effect of opiates.
    Fang FG; Fields HL; Lee NM
    J Pharmacol Exp Ther; 1986 Sep; 238(3):1039-44. PubMed ID: 3018217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
    Craft RM; Dykstra LA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):327-33. PubMed ID: 1309876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays.
    Takemori AE; Ho BY; Naeseth JS; Portoghese PS
    J Pharmacol Exp Ther; 1988 Jul; 246(1):255-8. PubMed ID: 2839664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice.
    Welch SP
    J Pharmacol Exp Ther; 1993 May; 265(2):633-40. PubMed ID: 8388455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.
    Paronis CA; Bergman J
    J Pharmacol Exp Ther; 2011 Feb; 336(2):488-95. PubMed ID: 21051498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that nor-binaltorphimine can function as an antagonist at multiple opioid receptor subtypes.
    Spanagel R; Almeida OF; Shippenberg TS
    Eur J Pharmacol; 1994 Oct; 264(2):157-62. PubMed ID: 7851478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-Funaltrexamine antagonizes the analgesic effects of mu and kappa agonists in the formalin test.
    Abbott FV
    Pharmacol Biochem Behav; 1990 Dec; 37(4):713-6. PubMed ID: 1965514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of specific opioid agonists and antagonists to delineate the vagally mediated antinociceptive and cardiovascular effects of intravenous morphine.
    Randich A; Robertson JD; Willingham T
    Brain Res; 1993 Feb; 603(2):186-200. PubMed ID: 8096421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.
    Vonvoigtlander PF; Lahti RA; Ludens JH
    J Pharmacol Exp Ther; 1983 Jan; 224(1):7-12. PubMed ID: 6129321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TENA, a selective kappa opioid receptor antagonist.
    Portoghese PS; Takemori AE
    Life Sci; 1985 Feb; 36(8):801-5. PubMed ID: 2983171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-gated K(+) channel openers enhance opioid antinociception: indirect evidence for the release of endogenous opioid peptides.
    Lohmann AB; Welch SP
    Eur J Pharmacol; 1999 Dec; 385(2-3):119-27. PubMed ID: 10607867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of central mu, delta-1, and kappa-1 opioid receptors in opioid-induced muscle rigidity in the rat.
    Vankova ME; Weinger MB; Chen DY; Bronson JB; Motis V; Koob GF
    Anesthesiology; 1996 Sep; 85(3):574-83. PubMed ID: 8853088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.